$0
UPDATE: Legend Discloses Carvykti’s Q2 2022 Revenue of $24M
On Thursday, July 21, Legend Biotech reported (6-K SEC) that Carvykti (JNJ / Legend’s BCMA CAR-T) generated approximately $24M in “net trade sales” in Q2 2022. Of note, during JNJ’s Q2 2022 earnings call, management highlighted that the first Carvykti sales had been recorded, but did not disclose its Q2 2022 revenue (see previous insight). The Celltelligence team will analyze how Carvykti’s revenue compares with key competitor Abecma (BMS’s BCMA CAR-T) after BMS releases its Q2 2022 financial results on July 27, 2022.